Amita Shukla

Founder & CEO, Vitamita

amitaAmita Shukla is an innovator and entrepreneur focused on discovering, developing, and scaling simple yet powerful ideas for human well-being. She is the founder and CEO of Vitamita and the author of Enduring Edge Until early 2012, she was a principal at New Enterprise Associates (NEA), one of the world’s largest and most active venture capital firms with over $13 billion in committed capital. During close to nine years on NEA’s healthcare team, Amita evaluated novel therapies, diagnostics, and medical technologies, invested in cutting-edge companies, and worked closely with scientists, doctors, and entrepreneurs to advance their innovations from the bench to the bedside. Earlier, she was the vice president of AmiKa Corp., a biomedical technology company where she developed and commercialized novel research tools–for which she holds 10 issued patents–until its acquisition by Harvard Bioscience (Nasdaq: HBIO). Previously, she founded two startups and was a healthcare analyst at Merrill Lynch. She has written about innovation for publications such as the MIT Technology Review.

Amita regularly mentors startups, advises organizations, and speaks to audiences of innovators, entrepreneurs, and leaders in industry, academia, government, and the military. In 2015, she was appointed as a Mentor in Residence at Johns Hopkins University to help its researchers and physicians realize the potential of their groundbreaking healthcare innovations. She has also served on the Johns Hopkins Medicine Alliance for Science and Technology Development since 2007. In 2010, she was Governor Martin O’Malley’s youngest appointee to the board of Maryland’s Technology Development Corporation (TEDCO), a national leader in seed/early-stage investing. In 2015, she was reappointed by Governor Larry Hogan. Amita also serves as a Life Science Council member for Springboard and as a founding board member of the Global Liver Institute, both driven by her passion for mentoring and supporting women entrepreneurs. Amita holds a BA in biochemistry from Harvard, where she was a senior editor at the Harvard Crimson, and an MBA from Stanford, where she led a team that won the university-wide Stanford business-plan competition for a novel cardiovascular device.